AbbVie Inc. $ABBV Stock Acquired by Sowell Financial Services LLC

Sowell Financial Services LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,301 shares of the company’s stock after buying an additional 3,985 shares during the quarter. Sowell Financial Services LLC’s holdings in AbbVie were worth $12,635,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Atticus Wealth Management LLC lifted its holdings in AbbVie by 10.6% during the 3rd quarter. Atticus Wealth Management LLC now owns 3,519 shares of the company’s stock worth $921,000 after buying an additional 336 shares in the last quarter. 365 WMG Private Fund I Primus Fund LLC acquired a new position in shares of AbbVie in the third quarter worth $506,000. Quadrant Capital Group LLC grew its stake in shares of AbbVie by 0.3% in the third quarter. Quadrant Capital Group LLC now owns 57,031 shares of the company’s stock worth $15,647,000 after acquiring an additional 183 shares in the last quarter. Bell Bank grew its stake in shares of AbbVie by 0.6% in the third quarter. Bell Bank now owns 54,278 shares of the company’s stock worth $14,199,000 after acquiring an additional 330 shares in the last quarter. Finally, Capstone Capital Management Ltd purchased a new stake in shares of AbbVie during the third quarter worth $987,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial
• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach
• Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie
• Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment.
• Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial

Analyst Ratings Changes

ABBV has been the topic of several analyst reports. Barclays increased their price objective on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday. Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Royal Bank Of Canada restated an “outperform” rating and set a $280.00 price target on shares of AbbVie in a report on Tuesday, October 13th. Citigroup upped their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $288.00 price target on shares of AbbVie in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $278.07.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie Stock Down 1.5%

NYSE ABBV opened at $284.63 on Thursday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40. The stock has a market capitalization of $502.89 billion, a PE ratio of 80.41, a price-to-earnings-growth ratio of 1.32 and a beta of 0.24. The firm has a 50 day moving average of $264.93 and a two-hundred day moving average of $240.92.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the firm posted $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.